Wells Fargo & Company MN Increases Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Wells Fargo & Company MN raised its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 21.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,928 shares of the company's stock after acquiring an additional 2,972 shares during the period. Wells Fargo & Company MN owned approximately 0.06% of Krystal Biotech worth $2,652,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new position in Krystal Biotech in the third quarter valued at $40,000. Avanza Fonder AB bought a new position in Krystal Biotech in the 4th quarter worth $119,000. KBC Group NV lifted its holdings in Krystal Biotech by 46.3% in the fourth quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after buying an additional 297 shares during the period. Blue Trust Inc. boosted its position in shares of Krystal Biotech by 74.4% during the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after purchasing an additional 433 shares in the last quarter. Finally, US Bancorp DE grew its position in shares of Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after buying an additional 82 shares during the period. Institutional investors own 86.29% of the company's stock.

Insider Activity

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company's stock.

Krystal Biotech Trading Down 0.4 %

NASDAQ KRYS traded down $0.69 during trading hours on Wednesday, hitting $169.88. 210,944 shares of the company's stock traded hands, compared to its average volume of 295,802. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34. The firm has a market capitalization of $4.91 billion, a P/E ratio of 56.82 and a beta of 0.75. The business's fifty day moving average price is $175.64 and its two-hundred day moving average price is $171.48.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm's quarterly revenue was up 116.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.30 EPS. On average, sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Jefferies Financial Group began coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target on the stock. HC Wainwright increased their price target on shares of Krystal Biotech from $221.00 to $240.00 and gave the company a "buy" rating in a report on Monday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Citigroup lifted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Finally, Chardan Capital raised their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $222.71.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).